Study | Treatments | Outcomes Assessed | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tedizolid | Tigecycline | Ceftaroline | Teicoplanin | Linezolid | Vancomycin | Daptomycin | Telavancin | EOT – all | EOT – ITT/mITT only | PTE/TOC – all | PTE/TOC – ITT/mITT only | EOT/PTE/TOC – MRSA only | Discontinuation due to AE – all | PTE/TOC – MRSA only (post hoc) | |
Aikawa et al., 2013 [22] | Â | Â | Â | Â | Â | x | x | Â | Â | Â | x | x | x | x | x |
Corey et al., 2010 [35] | Â | Â | x | Â | Â | xa | Â | Â | Â | Â | Â | Â | Â | Â | x |
Evers et al., 2013 [29] | Â | Â | Â | Â | Â | Â | x | x | Â | Â | x | x | Â | Â | Â |
Florescu et al., 2008 [32] | Â | x | Â | Â | Â | x | Â | Â | Â | Â | x | x | x | Â | x |
Itani et al., 2010 [23] | Â | Â | Â | Â | x | x | Â | Â | x | x | x | x | x | Â | x |
Kohno et al., 2007 [24] | Â | Â | Â | Â | x | x | Â | Â | x | Â | x | Â | x | Â | x |
Lin et al., 2008 [34] | Â | Â | Â | Â | x | x | Â | Â | x | Â | x | Â | Â | Â | Â |
Moran et al., 2014 [9] | x | Â | Â | Â | x | Â | Â | Â | x | x | x | x | Â | x | Â |
Pertel et al., 2009 [30] | Â | Â | Â | Â | Â | x | x | Â | Â | Â | x | x | Â | x | Â |
Prokocimer et al., 2013 [10] | x | Â | Â | Â | x | Â | Â | Â | x | x | x | x | x | x | x |
Sharpe et al., 2005 [25] | Â | Â | Â | Â | x | x | Â | Â | Â | Â | x | x | x | Â | x |
Stevens et al., 2002 [26] | Â | Â | Â | Â | x | x | Â | Â | Â | Â | x | x | x | Â | x |
Stryjewski et al., 2008 [33] | Â | Â | Â | Â | Â | x | Â | x | Â | Â | x | x | x | x | x |
Talbot et al., 2007 [31] | Â | Â | x | Â | Â | x | Â | Â | x | Â | x | x | b | x | x |
Weigelt et al., 2005 [27] | Â | Â | Â | Â | x | x | Â | Â | Â | Â | x | x | Â | x | Â |
Wilcox et al., 2004 [28] | Â | Â | Â | x | x | Â | Â | Â | x | x | Â | Â | Â | Â | Â |